Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia.
about
Gene therapy in Parkinson's disease: rationale and current statusAvailable and emerging treatments for Parkinson's disease: a reviewNeuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent PerspectivesCell Therapy for Parkinson's Disease: New Hope from Reprogramming TechnologiesParkinson's disease: gene therapiesPatient-specific induced pluripotent stem cells in neurological disease modeling: the importance of nonhuman primate modelsParkinson's disease gene therapy: success by design meets failure by efficacyTreating Parkinson's disease in the 21st century: can stem cell transplantation compete?Current Experimental Studies of Gene Therapy in Parkinson's DiseaseDelayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's diseaseIRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primatesA new quantitative rating scale for dyskinesia in nonhuman primates.Rescue of severe infantile hypophosphatasia mice by AAV-mediated sustained expression of soluble alkaline phosphataseAnimal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Critical aspects of clinical trial design for novel cell and gene therapies.Synaptic pathology and therapeutic repair in adult retinoschisis mouse by AAV-RS1 transfer.Design of a single AAV vector for coexpression of TH and GCH1 to establish continuous DOPA synthesis in a rat model of Parkinson's diseaseNeurotensin-Conjugated Reduced Graphene Oxide with Multi-Stage Near-Infrared-Triggered Synergic Targeted Neuron Gene Transfection In Vitro and In Vivo for Neurodegenerative Disease Therapy.Retinal Gene Therapy: Current Progress and Future Prospects.Serotype-dependent transduction efficiencies of recombinant adeno-associated viral vectors in monkey neocortexTwo decades of clinical gene therapy--success is finally mountingFocusing brain therapeutic interventions in space and time for Parkinson's disease.Long-term multilineage engraftment of autologous genome-edited hematopoietic stem cells in nonhuman primates.Direct and retrograde transduction of nigral neurons with AAV6, 8, and 9 and intraneuronal persistence of viral particlesEfficient gene delivery and selective transduction of astrocytes in the mammalian brain using viral vectors.Pervasive supply of therapeutic lysosomal enzymes in the CNS of normal and Krabbe-affected non-human primates by intracerebral lentiviral gene therapyGene-based therapies in Parkinson's disease.Large-scale chondroitin sulfate proteoglycan digestion with chondroitinase gene therapy leads to reduced pathology and modulates macrophage phenotype following spinal cord contusion injury.Gene therapy: a viable therapeutic strategy for Parkinson's disease?Gene therapy for Parkinson's disease: where are we now and where are we going?New non-oral drug delivery systems for Parkinson's disease treatment.Synthetic biology with surgical precision: targeted reengineering of signaling proteins.Viral vectors and delivery strategies for CNS gene therapy.A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting.New developments in lentiviral vector design, production and purification.Progress in gene therapy for neurological disorders.Gene therapy for Parkinson's disease: state-of-the-art treatments for neurodegenerative disease.Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indicationsRegenerative medicine for Parkinson's disease.
P2860
Q22241423-7679CE67-8DB5-429B-B13E-07733C5DC215Q24633444-8BF7B50C-103B-4471-8C00-6B072A32B0B4Q26747508-8FA045B2-EE61-46D7-9F24-C0C43CA7AF17Q26776041-BCC3474C-708F-4254-8998-79FB96A1A1CCQ26824184-F16A8968-3AA8-4586-A4C6-84FAF1C928A3Q26825524-FE624D81-7EA4-40F6-96A2-29B034183EEBQ26851325-B9037F2C-1CCA-41D9-9865-8204AD7C54ACQ27024152-BDFD177E-7D32-42B3-9A61-2710F61F386AQ33627771-64573256-4317-4041-8329-B8331D3E2109Q34473323-5E5BD4E5-5474-4753-997F-D638F30D4811Q34542164-DC39F114-7E12-47A2-AFFF-B0D8374015FDQ34771498-54F3F056-FF2F-4921-89E6-10B1F7AC5DD3Q35575693-49A5425F-88EC-4302-B617-F130FCF2C4A4Q35589979-BFAE92A5-5F48-40A1-A21F-8E39669084DEQ35614156-E9837FA7-FC22-4BAA-A0A6-360C40FB4647Q35664438-067DDDD9-692A-4DB0-938F-FE9E7BD1648BQ36040298-D168BB5E-8FA3-4BD4-B9A1-2E1989A671C6Q36085361-933EA932-859C-4D93-A2E7-3C010768B778Q36180141-2AE62DE6-2EC7-408F-BF85-007896799C73Q36306263-D63E2EFF-ED9F-4CEB-9868-CE15174E815AQ36508670-ED357BBD-D5DA-4C54-A5BD-5D6AAE25E67FQ36652351-FE355FBD-4D55-4AB8-AF4A-3B79A499C786Q36745293-84C47A4D-EB40-4012-9D2A-0B1AFCC2DC3BQ36920437-2FF73655-D0DE-442F-B87A-B511ADF5C1CBQ36945745-C232A04F-82A1-400F-BEA1-6B40BB829EE9Q36983576-1A2E230D-8D5F-48E7-B6ED-916D674D2217Q37453594-B74BA10F-27BF-41B0-9EB7-C1F292805C04Q37506503-A2A1A6B4-6AFC-4157-9029-ED767E4327C0Q37679296-13DBEA6D-F7CF-4469-BA48-B2EA74B95EEEQ37801855-A6AEF6B4-B91F-4AA3-B099-5FA22FEFF444Q37810994-04EB026D-A7BF-4F5A-946D-74D873564059Q37840165-23B5DC86-DBB5-45DB-9E68-31F9090403A3Q38016028-D721ABC6-0802-44C4-94FB-7E9AEAB3DCC2Q38029645-5B6FF2B6-574A-4DB9-BB7A-6ADB415C3C30Q38075068-937D32F5-071A-465B-B25D-947D7968B65EQ38099382-A55AF579-7240-46BC-A76D-01A0BC6D9F92Q38100997-4D44E4D9-063A-4B8B-B97E-691685A225A7Q38112216-147653AA-F1DF-464B-B1B2-334AED5DE2BEQ38166648-2494F88A-70A4-4F4F-898F-7FDFB04B260EQ38369065-9862DDAB-C6BD-4BB9-B4D2-10310A351FD6
P2860
Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Dopamine gene therapy for Park ...... without associated dyskinesia.
@en
Dopamine gene therapy for Park ...... without associated dyskinesia.
@nl
type
label
Dopamine gene therapy for Park ...... without associated dyskinesia.
@en
Dopamine gene therapy for Park ...... without associated dyskinesia.
@nl
prefLabel
Dopamine gene therapy for Park ...... without associated dyskinesia.
@en
Dopamine gene therapy for Park ...... without associated dyskinesia.
@nl
P2093
P2860
P50
P921
P1476
Dopamine gene therapy for Park ...... without associated dyskinesia
@en
P2093
Caroline Jan
Denise M Day
G Scott Ralph
James E Miskin
Kyriacos A Mitrophanous
Masahiro Shin
Nicholas D Mazarakis
Philippe Hantraye
Sabrina Boulet
Stéphane Palfi
P2860
P356
10.1126/SCITRANSLMED.3000130
P407
P577
2009-10-01T00:00:00Z